• Kuva Labs to Acquire Lisata Therapeutics for $21.38M
Lisata Therapeutics - Latest News and Information
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Technology Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Tuesday recap

NewsDealsSocialBlogsVideosPodcasts
HomeLisata Therapeutics
Lisata Therapeutics logo

Lisata Therapeutics

0 followers

LSTA

Performance

About Lisata Therapeutics

Lisata Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for advanced solid tumors, with a pipeline centered on tumor-penetrating delivery and targeted cancer treatments. The company emphasizes CendR Platform technology and CD34+ cell-based approaches to enhance drug delivery and modulate the tumor microenvironment. Headquartered in the United States (Basking Ridge, New Jersey), Lisata operates a broad research and development program targeting pancreatic cancer, cholangiocarcinoma, and other solid tumors.

Recent News

No recent news for this company.

Recent Deals

Kuva Labs to Acquire Lisata Therapeutics for $21.38M

March 6, 2026

Key Team Members

Dr. David J. Mazzo

President and CEO

Key Facts

HQ Location

United States

Founded

2006

Employees

11 - 50

Status

Public

Website

https://lisata.com